Core Insights - Establishment Labs reported a strong fourth quarter and full-year 2025, driven by rapid growth in its U.S. Motiva breast implant business and improving profitability metrics [5][8] Financial Performance - The company reported a fourth-quarter net loss from operations of $3.9 million, down 79% from Q4 2024, and adjusted EBITDA of positive $5.5 million, compared to negative $13.1 million in the year-ago quarter [1] - Fourth-quarter revenue was $64.6 million, up 45.2% versus Q4 2024, with full-year 2025 revenue at $211.1 million, an increase of 27.2% over 2024 [4][8] - Gross margin for Q4 was 70.5%, up 200 basis points year over year, with full-year gross margin up 330 basis points versus 2024 [2][7] Market Performance - In the U.S., Motiva revenue was $17.3 million in Q4 and $45.6 million for 2025, with the company exiting 2025 with approximately 20% augmentation market share [3][8] - The company has onboarded over 1,500 U.S. accounts since the late-2024 launch, with strong surgeon interest in Motiva [13] Growth Drivers - The minimally invasive Preserve platform is gaining traction, targeting over 200 trained U.S. surgeons and expected to generate more than $30 million in demand in 2026 [6][16] - Management plans to expand the U.S. sales force by up to 15 representatives in 2026, focusing on experienced industry veterans [14] Future Guidance - For 2026, Establishment Labs guided revenue to $264 million to $266 million, representing 25.1% to 26.0% growth, with expectations for gross margin expansion of 200 to 300 basis points [10] - The company anticipates reaching a first positive cash flow quarter in 2026, with full-year cash flow positivity expected in 2027 [9][19] Product Development - The company submitted Motiva implants to the FDA in December 2025 for primary and revision breast reconstruction, which could effectively double its U.S. total addressable market [17] - Management expressed confidence in obtaining FDA approval for small sizes in the first half of 2026 and mentioned additional pipeline programs for future U.S. introduction [18]